Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy.

Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Mauro Moroni(University of Milan), Daniela Frasca(University of Miami), C. Sguotti, María Orietta Borghi(IRCCS Istituto Auxologico Italiano), P. Buzzetti, Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Adriano Lazzarin(Vita-Salute San Raffaele University), Gino Doria, Pier Luigi Meroni(IRCCS Istituto Auxologico Italiano)
PubMed
March 1, 1987
Cited by 13

Related Papers

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373